/**

Concord Biotech FY26: Softer Year, Bigger Build-Out

Concord Biotech closed FY26 with a clear mismatch between operational build-out and near-term financial delivery. Consolidated revenue came in at 1,054.9 crore for FY26, down from 1,200.1 crore in FY25. Profitability followed the same direction, with EBITDA at 367.4 crore (FY25: 506.3 crore) and PAT at 259.2 crore (FY25: 371.6 crore).

The company attributed the weaker year to timing disruptions rather than structural issues. In its management commentary and the FY26 investor presentation, Concord pointed to delayed customer procurement decisions, uncertainty around US tariff measures, and geopolitical disruptions across key markets. Customers also shifted from bulk purchases to staggered quarter-wise procurement, which lowered reported volumes during the year and pushed part of the demand into subsequent periods.

FY26 performance in context

Despite the revenue decline, the gross margin improved. FY26 gross profit margin rose to 76.7% compared with 74.5% in FY25. This indicates product economics remained resilient even as customer ordering behaviour turned unpredictable. The sharper pressure came at the operating level. FY26 EBITDA margin fell to 34.8% from 42.2% in FY25, reflecting the combined effect of lower operating leverage and higher cost base. The company also provided a disclosure that excluding the impact of the formulation facility and expenses related to the newly incorporated US subsidiary Stellan Biotech, EBITDA margin would have been 38.8% for FY26.

The quarter picture was similar. Q4FY26 revenue was 326.1 crore versus 429.9 crore in Q4FY25. Q4FY26 EBITDA fell to 118.5 crore from 190.4 crore, and PAT declined to 88.5 crore from 140.4 crore.

Mix: APIs remain the core, formulations steady

Concord remains primarily an API company. FY26 API revenue was 828.8 crore, accounting for 79% of consolidated revenue. Formulations revenue stood at 226.1 crore, contributing 21%. In Q4, APIs formed 81% of revenue and formulations 19%.

The presentation positions the formulations strategy as an extension of its backward integration benefits, with a B2B model across regulated and emerging markets. In India, the company operates via a B2B and B2C model. On the dosage side, the portfolio spans oral solids and injectables, with injectables receiving a major strategic push in FY26.

What disrupted FY26: timing, documentation, and uncertainty

The company listed multiple challenges encountered during FY26.

One issue was a delay in supply to the European Union due to a delayed Written Confirmation from CDSCO, which the presentation says impacted EU supplies for about three months. Second, the US saw a procurement pattern change where customers moved from bulk purchases to staggered quarter-wise ordering. Third, global tariff and trade uncertainty slowed procurement in the first half of the year, with the company noting that demand recovered gradually in the second half.

Concord also cited Middle East headwinds due to geopolitical tensions, affecting both tender-based and routine supplies. Additionally, a US Veterans Affairs tender was not finalized during the year, resulting in lower sales for FY26.

The company stated its focus areas included strengthening customer engagement and supply chain agility, improving order-flow conversion and pipeline visibility, and monitoring global policy changes with mitigation planning. It also explicitly characterized the challenges as timing and transition-led, not structural.

FY26 strategy: regulatory strength, injectables, CDMO, and a US footprint

While FY26 was financially weaker, the presentation shows the company using the year to strengthen platforms. Regulatory compliance is highlighted as a core enabler for global supplies. Concord stated it successfully completed USFDA, EU GMP, Russian GMP, NAFDAC and WHO-GMP inspections across facilities.

The year also marked the push to scale up injectables. Concord highlighted commercialization of its new injectables facility and stated that WHO-GMP certification enables entry into domestic own-brand and contract opportunities.

On the API side, the company highlighted CDMO and second-source opportunities. It stated it commenced supplies of Concord APIs to two innovator companies. It also mentioned steady progress in customer acquisition for Nystatin, launched last year, and commercialization of Fusidic acid in FY26, noting limited competition mainly from European manufacturers. The presentation also refers to active discussions with innovators for generic API supplies and CDMO projects that are in advanced stages.

A notable strategic step was building a US commercial footprint through Stellan Biotech Inc. The presentation states the entity obtained requisite licenses and sales are expected to commence during the first half of the year, enabling direct marketing, distribution, and commercialization of Concord Biotech products in the US.

Beyond the core, Concord also stated it entered Cell and Gene Therapy through an investment in Cellmune Biotech and incorporated Concord Lifegen to strengthen domestic formulations strategy. It also stated it commenced commercialization of its soft gel facility.

Balance sheet and cash flow: operating cash remained healthy

The abridged cash flow statement shows net cash from operating activities of 266.9 crore in FY26 versus 244.5 crore in FY25. Cash generated from operations was 367.3 crore in FY26.

On the balance sheet, total assets stood at 2,234.7 crore as of March 2026, with total equity of 2,015.1 crore.

The presentation also disclosed a steady reduction in customer concentration over multiple years. Contribution from the top 10 customers declined to 37.6% in FY26 from 47.7% in FY22.

What to track into FY27

Management commentary in the presentation states the company remains highly optimistic about delivering strong outperformance in FY27, driven by current order enquiries and a customer acquisition pipeline. While this is qualitative and not numerical guidance, the underlying message is that the FY26 disruption was largely about ordering patterns, approvals, and timing, with demand expected to normalise.

For investors, the key question is whether the ongoing investments translate into more stable order flow and improved operating leverage. The most important markers to watch will be ramp-up of injectables and other formulation capacities, traction from CDMO and innovator supplies, and the pace at which the US commercial presence begins contributing.

Concord’s FY26 results show a company absorbing short-term volatility while expanding its addressable opportunity set. The financial reset is visible in margins, but the strategy described in the presentation is clearly aimed at building the next phase of growth on a platform of regulatory compliance, fermentation capabilities, and deeper customer relationships. */